| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYL4 |
| Uniprot No | P12829 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-197aa |
| 氨基酸序列 | MAPKKPEPKKEAAKPAPAPAPAPAPAPAPAPEAPKEPAFDPKSVKIDFTA DQIEEFKEAFSLFDRTPTGEMKITYGQCGDVLRALGQNPTNAEVLRVLGK PKPEEMNVKMLDFETFLPILQHISRNKEQGTYEDFVEGLRVFDKESNGTV MGAELRHVLATLGEKMTEAEVEQLLAGQEDANGCINYEAFVKHIMSGLEH HHHHH |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYL4重组蛋白研究的参考文献示例(注：以下为模拟文献，实际文献需通过学术数据库检索确认)：
1. **文献名称**：*"Recombinant Expression and Functional Analysis of Human MYL4 in Cardiomyocyte Contractility"*
**作者**：Li, X. et al.
**摘要**：本研究通过大肠杆菌系统成功表达并纯化了重组人MYL4蛋白，体外实验表明该蛋白可增强心肌细胞肌球蛋白ATP酶活性，提示其在心肌收缩中的调控作用。
2. **文献名称**：*"Structural Insights into MYL4-Myosin Heavy Chain Interaction via Recombinant Protein Complex Modeling"*
**作者**：Yamamoto, K. et al.
**摘要**：利用重组MYL4蛋白与肌球蛋白重链共结晶技术，解析了二者结合的分子机制，为遗传性心肌病的致病突变位点提供了结构生物学依据。
3. **文献名称**：*"MYL4 Knockout Mice Exhibit Altered Sarcomere Organization: Rescue by Recombinant MYL4 Delivery"*
**作者**：Chen, R. et al.
**摘要**：通过腺病毒载体递送重组MYL4至基因敲除小鼠心脏，恢复了肌节组装异常，证实MYL4在维持肌原纤维结构完整性中的关键功能。
4. **文献名称**：*"High-Yield Production of Recombinant MYL4 in Insect Cells for Antibody Development"*
**作者**：Garcia, S. et al.
**摘要**：优化杆状病毒-昆虫细胞表达系统实现MYL4的高效分泌表达，并基于此蛋白制备了特异性单克隆抗体，为临床诊断提供了新工具。
---
**建议**：实际文献可通过PubMed/Google Scholar以“MYL4 recombinant protein”、“MYL4 gene cloning”等关键词检索，重点关注蛋白功能、疾病关联或结构研究方向。
**Background of MYL4 Recombinant Protein**
MYL4 (myosin light chain 4) is a regulatory protein component of myosin, a molecular motor critical for muscle contraction and cellular motility. It belongs to the myosin light chain family, which modulates the ATPase activity of myosin heavy chains and influences actin-myosin interactions. MYL4 specifically associates with the myosin heavy chain in cardiac and skeletal muscle, playing a role in maintaining contractile function and structural integrity.
The MYL4 gene is located on human chromosome 17 and encodes a small, calcium-binding protein. Mutations in MYL4 have been linked to inherited cardiomyopathies, such as familial hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), highlighting its importance in cardiac health. Studies suggest that MYL4 dysfunction disrupts sarcomere organization, leading to impaired muscle contraction and pathological cardiac remodeling.
Recombinant MYL4 protein is engineered using expression systems like *E. coli* or mammalian cells to ensure proper post-translational modifications. This protein is purified for use in biochemical assays, structural studies, and functional investigations. Researchers employ recombinant MYL4 to study its interactions with myosin heavy chains, calcium signaling, and its role in disease mechanisms.
In drug discovery, MYL4 serves as a potential therapeutic target for cardiomyopathy. Its recombinant form also aids in developing diagnostic tools for detecting MYL4-related mutations. Additionally, studies in model organisms, such as zebrafish or mice, utilize recombinant MYL4 to explore its role in embryonic development and tissue-specific functions.
Overall, MYL4 recombinant protein is a vital tool for deciphering the molecular basis of muscle contraction, disease pathology, and advancing targeted therapies for cardiac disorders. Its study bridges basic research and clinical applications, offering insights into both normal physiology and disease.
(Word count: 298)
×
